What podcasts say about Genmab
Every statement, with the speaker, the exact quote and the moment it was said.
What experts have said about Genmab
6 statements · 6 positive
Genmab’s ovarian-cancer trial showed a 60–70% reduction in death.
“with a 60% to 70% reduction in death.”
Open the episode · Episode 201 - October 30, 2026Listen at 54:42
Genmab’s strong oncology data may justify a higher stock valuation.
“this is a stock that you could see is now getting remunerated”
Open the episode · Episode 201 - October 30, 2026Listen at 56:48
Genmab and AbbVie’s combination medicine reduced lymphoma progression or death risk by over 50%.
“it's cutting the risk of disease progression or death by more than 50%”
Open the episode · Genmab Gains, Sabadell Rises, Vend TumblesListen at 0:58
Positive clinical results are reducing uncertainty around Genmab’s sales expectations.
“these positive results are helping to de-risk sales expectations”
Open the episode · Genmab Gains, Sabadell Rises, Vend TumblesListen at 1:27
GenmAb exceeded revenue and profit expectations and raised its annual outlook.
“GenmAb makes antibody therapeutics, so reported better than expected revenue, better than expected profit for the second quarter and it also boosted its outlook for the year.”
Open the episode · Kingspan Soars, Daimler Truck Slumps, Genmab JumpsListen at 3:30
GenmAb’s lymphoma program could represent a $600 million opportunity in 2035.
“that could be a $600 million commercial opportunity in 2035, according to Bloomberg Intelligence”
Open the episode · Kingspan Soars, Daimler Truck Slumps, Genmab JumpsListen at 4:02
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.